Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

   Recruiting · Phase 2 · Follicular Lymphoma

   NCT06350318 · Beone Medicines USA, Inc. · 1 U.S. investigator

   $150,764research payments

2. Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)

   Active, not recruiting · Dermatitis, Atopic

   NCT03428646 · Regeneron Pharmaceuticals, Inc. · 44 U.S. investigators

   $150,454research payments

3. Active Removal of IntraCerebral Hematoma Via Active Irrigation

   Status unknown · Not applicable · Cerebral Hemorrhage

   NCT05118997 · Irras USA, Inc. · 3 U.S. investigators

   $149,616research payments

4. A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors

   Recruiting · Phase 1 · Advanced Solid Tumor

   NCT06803680 · Beone Medicines USA, Inc. · 3 U.S. investigators

   $148,742research payments

5. CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

   Active, not recruiting · Phase 2 · Sarcoma, Ewing

   NCT05440786 · Eli Lilly and Company · 3 U.S. investigators

   $148,512research payments

6. A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

   Terminated · Phase 1, Phase 2 · Squamous Cell Carcinoma of Head and Neck

   NCT03829501 · Sanofi US Services Inc. · 3 U.S. investigators

   $147,864research payments

7. Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis

   Completed · Phase 4 · Psoriasis

   NCT05478499 · E.r. Squibb & Sons, L.l.c. · 13 U.S. investigators

   $147,609research payments

8. Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

   Active, not recruiting · Phase 1 · Cholangiocarcinoma

   NCT04521686 · Eli Lilly and Company · 4 U.S. investigators

   $147,448research payments

9. Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)

   Completed · Phase 1, Phase 2 · Respiratory Syncytial Virus Infection

   NCT05687279 · Sanofi Pasteur Inc. · 5 U.S. investigators

   $147,404research payments

10. PRV-3279-2a Trial in Systemic Lupus

    Terminated · Phase 2 · Systemic Lupus Erythematosus

    NCT05087628 · Sanofi US Services Inc. · 18 U.S. investigators

    $147,026research payments

11. Safety and Effectiveness of TurbAlign™ for Middle Turbinate Medialization After Functional Endoscopic Sinus Surgery

    Active, not recruiting · Not applicable · Sinus Endoscopic Surgery

    NCT07027267 · Spirair, Inc. · 5 U.S. investigators

    $146,403research payments

12. Assessment of GORE® SYNECOR Biomaterial in Focused Patient Populations and Long-Term Application

    Active, not recruiting · Hernia, Ventral

    NCT05094089 · W. L. Gore & Associates, Inc. · 8 U.S. investigators

    $146,184research payments

13. A Study of DS-9606a in Patients With Advanced Solid Tumors

    Terminated · Phase 1 · Advanced Cancer

    NCT05394675 · Daiichi Sankyo Inc. · 2 U.S. investigators

    $145,788research payments

14. The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

    Recruiting · Phase 3 · Sickle Cell Disease

    NCT06975865 · Sanofi US Services Inc. · 6 U.S. investigators

    $144,261research payments

15. Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

    Active, not recruiting · Phase 4 · Lymphoma, B-Cell

    NCT03229200 · AbbVie Inc. · 22 U.S. investigators

    $143,968research payments

16. A Registry for Participants With Chronic Hypoparathyroidism

    Completed · Hypoparathyroidism

    NCT01922440 · Takeda Pharmaceuticals U.S.A., Inc. · 28 U.S. investigators

    $143,851research payments

17. Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study

    Active, not recruiting · Phase 2 · Chronic Rhinosinusitis With Nasal Polyps

    NCT06914908 · Sanofi US Services Inc. · 5 U.S. investigators

    $143,124research payments

18. Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

    Active, not recruiting · Phase 3 · Multiple Myeloma

    NCT04975997 · E.r. Squibb & Sons, L.l.c. · 7 U.S. investigators

    $142,493research payments

19. A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants

    Completed · Phase 1 · Healthy

    NCT06186622 · Eli Lilly and Company · 2 U.S. investigators

    $142,448research payments

20. Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

    Completed · Phase 3 · Breast Cancer

    NCT03734029 · Daiichi Sankyo Inc. · 12 U.S. investigators

    $141,395research payments

21. BlueWind RENOVA iStim™ System for the Treatment of OAB

    Completed · Not applicable · Treatment of Patients Suffering From Overactive Bladder (OAB)

    NCT03596671 · Bluewind Medical · 15 U.S. investigators

    $140,963research payments

22. A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

    Terminated · Phase 2 · Heart Failure

    NCT05592275 · Eli Lilly and Company · 13 U.S. investigators

    $140,435research payments

23. A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.

    Recruiting · Phase 1 · Hepatic Insufficiency

    NCT07401862 · Eli Lilly and Company · 3 U.S. investigators

    $140,185research payments

24. Tazemetostat Plus CHOP in 1L T-cell Lymphoma

    Withdrawn · Phase 2 · Lymphoma

    NCT06692452 · Ipsen Biopharmaceuticals, Inc · 1 U.S. investigator

    $140,000research payments

25. NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma

    Terminated · Phase 2, Phase 3 · Non-Hodgkin Lymphoma

    NCT05664217 · E.r. Squibb & Sons, L.l.c. · 4 U.S. investigators

    $139,546research payments

26. Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia

    Terminated · Phase 2 · Acute Myeloid Leukemia

    NCT04994808 · Medexus Pharma, Inc. · 1 U.S. investigator

    $138,552research payments

27. Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

    Completed · Phase 3 · Heavy Menstrual Bleeding

    NCT03271489 · AbbVie Inc. · 12 U.S. investigators

    $138,427research payments

28. Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone

    Completed · Phase 3 · Graft Versus Host Disease (GVHD)

    NCT04167514 · Csl Behring · 1 U.S. investigator

    $138,266research payments

29. A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin

    Active, not recruiting · Phase 2 · Diabetes Mellitus, Type 2

    NCT07215312 · Eli Lilly and Company · 6 U.S. investigators

    $137,931research payments

30. Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine

    Completed · Phase 3 · Chronic Migraine

    NCT05216263 · AbbVie Inc. · 24 U.S. investigators

    $136,952research payments

31. SCS as an Option for Chronic Low Back and/or Leg Pain Instead of Surgery

    Completed · Not applicable · Chronic Pain

    NCT04676022 · Boston Scientific Corporation · 13 U.S. investigators

    $136,893research payments

32. A Patient Registry Study for Patients Treated With Voretigene Neparvovec in US

    Completed · Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy

    NCT03597399 · Spark Therapeutics, Inc. · 9 U.S. investigators

    $136,268research payments

33. A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)

    Terminated · Phase 2 · Familial Partial Lipodystrophy

    NCT05088460 · Regeneron Pharmaceuticals, Inc. · 2 U.S. investigators

    $134,764research payments

34. A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

    Completed · Phase 3 · Chronic Lymphocytic Leukemia

    NCT03734016 · Beigene, Ltd. · 5 U.S. investigators

    $133,910research payments

35. Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

    Completed · Phase 2 · Multiple Myeloma

    NCT02719613 · E.r. Squibb & Sons, L.l.c. · 7 U.S. investigators

    $133,270research payments

36. Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

    Active, not recruiting · Phase 1 · Myelofibrosis (MF)

    NCT04454658 · AbbVie Inc. · 6 U.S. investigators

    $132,315research payments

37. A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1

    Recruiting · Phase 1, Phase 2 · Myotonic Dystrophy

    NCT06844214 · Sanofi US Services Inc. · 3 U.S. investigators

    $132,215research payments

38. Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease

    Withdrawn · Phase 2 · Chronic Kidney Disease

    NCT06598631 · Eli Lilly and Company · 9 U.S. investigators

    $131,038research payments

39. Safety and Efficacy of FVIIa to Prevent Excessive Bleeding in Hemophilia Patients With Inhibitors Undergoing Major Surgery

    Terminated · Phase 3 · Hemophilia

    NCT05695391 · Hema Biologics, LLC · 1 U.S. investigator

    $130,843research payments

40. Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

    Recruiting · Phase 1 · Renal Cell Carcinoma

    NCT06966024 · Deciphera Pharmaceuticals Inc. · 3 U.S. investigators

    $130,413research payments

41. A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

    Completed · Phase 1, Phase 2 · Relapsed Solid Tumor

    NCT04238819 · Eli Lilly and Company · 6 U.S. investigators

    $130,231research payments

42. Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia

    Active, not recruiting · Phase 2 · Chronic Lymphocytic Leukemia

    NCT02629809 · AbbVie Inc. · 1 U.S. investigator

    $129,818research payments

43. Inhaled Nitric Oxide After Out-of-Hospital Cardiac Arrest

    Terminated · Phase 2 · Heart Arrest, Out-Of-Hospital

    NCT03079102 · Mallinckrodt Hospital Products Inc. · 1 U.S. investigator

    $129,558research payments

44. Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease

    Completed · Phase 2 · Alzheimer's Disease (AD)

    NCT05771428 · AbbVie Inc. · 20 U.S. investigators

    $128,630research payments

45. Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study

    Recruiting · Not applicable · Atrial Fibrillation (AF)

    NCT06935591 · Vektor Medical Inc. · 3 U.S. investigators

    $127,729research payments

46. The BEAR III Trial for Bridge-Enhanced ACL (Anterior Cruciate Ligament) Restoration

    Active, not recruiting · Not applicable · Anterior Cruciate Ligament Injury

    NCT03348995 · Miach Orthopaedics, Inc. · 7 U.S. investigators

    $127,492research payments

47. GORE® ENFORM Biomaterial Product Study

    Recruiting · Not applicable · Hernia, Ventral

    NCT04718168 · W. L. Gore & Associates, Inc. · 6 U.S. investigators

    $127,477research payments

48. Physio-Anatomy Clinical Data Collection Study

    Recruiting · Coronary Stenosis

    NCT05312164 · Gentuity, LLC · 6 U.S. investigators

    $127,448research payments

49. A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

    Completed · Phase 3 · Childhood Absence Epilepsy

    NCT05109234 · UCB SA · 6 U.S. investigators

    $126,904research payments

50. Study Assessing CLENPIQ as Bowel Preparation for Pediatric Colonoscopy

    Recruiting · Phase 1, Phase 2 · Bowel Preparation

    NCT04113382 · Ferring International Pharmascience Center US · 5 U.S. investigators

    $126,834research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.